WNT7A and neoplasm: Targeting Wnt7a with either of two independent shRNAs (Supplementary Fig. 6a) has no effect on primary tumour growth (Fig. 7a) but results in an overall trend to decreased αSMA and fibroblast activation protein (FAP) expression by tumour fibroblasts (Supplementary Fig. 6b).